TuisB1NT34 • BVMF
add
Biontech Se Bdr
Vorige sluiting
R$33,12
Dagwisseling
R$33,60 - R$34,45
Jaarwisseling
R$26,80 - R$49,05
Markkapitalisasie
23,34 mjd USD
Gemiddelde volume
666,00
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 182,80 m | -2,56% |
Bedryfskoste | 593,40 m | -6,05% |
Netto inkomste | -415,80 m | -31,96% |
Netto winsgrens | -227,46 | -35,43% |
Wins per aandeel | -1,73 | -32,06% |
EBITDA | -451,60 m | 2,84% |
Effektiewe belastingkoers | 6,65% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 14,11 mjd | -9,94% |
Totale bates | 21,18 mjd | -4,83% |
Totale aanspreeklikheid | 2,26 mjd | -1,43% |
Totale ekwiteit | 18,93 mjd | — |
Uitstaande aandele | 240,39 m | — |
Prys om te bespreek | 0,42 | — |
Opbrengs op bates | -5,65% | — |
Opbrengs op kapitaal | -6,36% | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -415,80 m | -31,96% |
Kontant van bedrywe | -780,70 m | -146,04% |
Kontant van beleggings | 1,25 mjd | 154,11% |
Kontant van finansiering | -13,80 m | -76,92% |
Netto kontantverandering | 423,00 m | 115,74% |
Beskikbare kontantvloei | -1,37 mjd | -175,36% |
Meer oor
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
HUB
Gestig
2008
Webwerf
Werknemers
6 772
